RT Journal Article
SR Electronic
T1 Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.11.22283166
DO 10.1101/2022.12.11.22283166
A1 Chalkias, Spyros
A1 Whatley, Jordan
A1 Eder, Frank
A1 Essink, Brandon
A1 Khetan, Shishir
A1 Bradley, Paul
A1 Brosz, Adam
A1 McGhee, Nichole
A1 Tomassini, Joanne E.
A1 Chen, Xing
A1 Zhao, Xiaoping
A1 Sutherland, Andrea
A1 Shen, Xiaoying
A1 Girard, Bethany
A1 Edwards, Darin K.
A1 Feng, Jing
A1 Zhou, Honghong
A1 Walsh, Stephen
A1 Montefiori, David C.
A1 Baden, Lindsey R.
A1 Miller, Jacqueline M.
A1 Das, Rituparna
YR 2022
UL http://medrxiv.org/content/early/2022/12/13/2022.12.11.22283166.abstract
AB Background Information on the safety and immunogenicity of the omicron BA.4/BA.5-containing bivalent booster mRNA-1273.222 are needed.Methods In this ongoing, phase 2/3 trial, 50-μg mRNA-1273.222 (25-μg each ancestral Wuhan-Hu-1 and omicron BA.4/BA.5 spike mRNAs) is compared to 50-μg mRNA-1273, administered as second boosters in adults who previously received a 2-injection (100-μg) primary series and first booster (50-μg) dose of mRNA-1273. The primary objectives were safety and immunogenicity 28 days post-boost.Results Participants received 50-μg of mRNA-1273 (n=376) or mRNA-1273.222 (n=511) as second booster doses. Omicron BA.4/BA.5 and ancestral SARS-CoV-2 D614G neutralizing antibody geometric mean titers (GMTs [95% confidence interval]) after mRNA-1273.222 (2324.6 [1921.2-2812.7] and 7322.4 [6386.2-8395.7]) were significantly higher than mRNA-1273 (488.5 [427.4-558.4] and 5651.4 (5055.7-6317.3) respectively, at day 29 post-boost in participants with no prior SARS-CoV-2-infection. A randomly selected subgroup (N=60) of participants in the mRNA-1273.222 group also exhibited cross-neutralization against the emerging omicron variants BQ.1.1 and XBB.1. No new safety concerns were identified with mRNA-1273.222.Vaccine effectiveness was not assessed in this study; in an exploratory analysis 1.6% (8/511) of mRNA-1273.222 recipients had Covid-19 post-boost.Conclusion The bivalent omicron BA.4/BA.5-containing vaccine mRNA-1273.222 elicited superior neutralizing antibody responses against BA.4/BA.5 compared to mRNA-1273, with no safety concerns identified.(Supported by Moderna; ClinicalTrials.gov Identifier: NCT04927065)Competing Interest StatementJW, FE, BE, SK, PB and AB have nothing to disclose; XS and DCM report funding from Moderna, Inc. for pseudovirus neutralization assays performed in the study; SRW has conducted clinical trials funded by NIAID/NIH Moderna, Inc., Janssen Vaccines, and Sanofi Pasteur; LRB is a co-primary principal investigator of the COVE trial funded by NIAID and conducted in conjunction with Moderna, Inc. SC, NMcG, XC, XZ, AS, BG, DKE, JF, HZ, JMM and RD are employees of Moderna, Inc. and may hold stock/stock options in the company. JET is a Moderna consultant.Clinical TrialClinicalTrials.gov NCT04927065Funding StatementThis study was funded by Moderna, Inc., Cambridge, Massachusetts, USA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial is being conducted in accordance with the International Council for Technical Requirements for Registration of Pharmaceuticals for Human Use, Good Clinical Practice Guidance, and applicable government regulations. The central Institutional Review Board/Ethics Committee, Advarra, Inc., 6100 Merriweather Drive, Columbia, MD 21044 approved the protocol and consent forms. All participants provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs the trial is ongoing, access to patient-level data and supporting clinical documents by qualified external researchers may be available upon request and subject to review once the trial is complete.